Health

Frontier Pharma: Orphan and Rare Dermatological Diseases – First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

Press Release

Summary     

The ”Orphan and Rare Dermatological Diseases Market” Report is a valuable source of knowledge for understanding world’s main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast.

Description

Orphan and rare dermatological diseases Market are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases.

Disease visibility can also have a profoundly negative impact on patient confidence. Unmet need within the orphan and rare dermatology market is extremely high with some diseases having no effective treatments. The market is highly genericized and dominated to a large extent by products acting on hormones and their receptors.

Most of these are corticosteroids and are used for symptom management with no disease-modifying effects. There is a significant unmet need for more efficacious disease-modifying treatments and safer treatment options across orphan and rare dermatological diseases, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues associated with the long-term use of available treatments.

Access This Orphan and Rare Dermatological Diseases Market Report @ http://www.arcognizance.com/report/frontier-pharma-orphan-and-rare-dermatological-diseases-first-in-class-therapies-demonstrate-potential-disease-modifying-effects-in-areas-of-high-unmet-need-such-as-epidermolysis-bullosa

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key indications,

systemic sclerosis (scleroderma)

alopecia

epidermolysis bullosa (EB)

pemphigus vulgaris

vitiligo and cutaneous lupus erythematosus (CLE)

as these conditions have the largest pipelines within the therapy area.

Scope
– There is a strong need for innovative new therapies across the orphan and rare dermatology market. How are orphan and rare dermatological diseases currently managed? What are the greatest unmet needs within this market?
– There are 262 pipeline products in development across all orphan and rare dermatological diseases. How does the composition of the pipeline compare with that of the existing market? Which molecular targets are most frequently acted upon by pipeline drugs? How do products in development for the key indications differ in terms of molecule type?
– Over one-third of pipeline products with a disclosed molecular target are first-in-class. How does the proportion of first-in-class products in development differ in terms of stage of development, molecule type and molecular target class? Which are the most promising first-in-class targets?
– The deals landscape has become more active in recent years. Which indications and products have attracted the highest deal values?

Get Sample for Orphan and Rare Dermatological Diseases Market Report @ http://www.arcognizance.com/enquiry-sample/134244

Reasons to buy
This report will allow you to:
– Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
– Visualize the composition of the market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
– Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
– Assess the therapeutic potential of first-in-class molecular targets. Using a proprietary matrix, first-in-class targets have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
– Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Some Points Covered in Table of Contents:

1 Table of Contents 2

2 Executive Summary 6

3 The Case for Innovation 7

4 Clinical and Commercial Landscape 11

5 Assessment of Pipeline Product Innovation 27

6 Signaling Network, Disease Causation and Innovation Alignment 47

7 First-in-Class Molecular Target Evaluation 52

8 Strategic Consolidations 67

9 Appendix 79

Buying This Orphan and Rare Dermatological Diseases Market Report @ http://www.arcognizance.com/discount/134244

About Us:

http://arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics” based on the data collection facilities of big data, the face of “business research facilities” has changed drastically  . With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the “out of the box” developments in the market.

Contact Us:

Matt Wilson,

100 Church street, 8th floor,

Manhattan, New york, 10007

Phone No: +1 (646) 434-7969

Email: [email protected]

RSS blogs